How often do ruxolitinib brands recommend dosing?

Recommended Dosing Strategies for Ruxolitinib Brands

Ruxolitinib, a Janus kinase (JAK) inhibitor, is used to treat myelofibrosis and polycythemia vera. The frequency at which ruxolitinib brands recommend dosing varies depending on the specific indication and patient population.

According to Jakafi, the brand name for ruxolitinib, the recommended dosing is as follows: [1]

* For the treatment of myelofibrosis, the recommended dose is 5 mg twice daily, taken orally with or without food.
* For the treatment of polycythemia vera, the recommended dose is 10-15 mg twice daily, taken orally with or without food.

Another brand, Inrebic (ruxolitinib), recommends the following dosing: [2]
* For the treatment of myelofibrosis, the recommended dose is 20 mg twice daily for the first 4 weeks, then 10 mg twice daily.
* For the treatment of graft-versus-host disease (GVHD) after failure of prior therapy, the recommended dose is 10 mg twice daily.

Tolerability and Dose Adjustments

Ruxolitinib can be tolerated in most patients, but dose adjustments are necessary in cases of liver enzyme elevations, renal impairment, or severe neutropenia.

According to the prescribing information for Jakafi, dose adjustment is recommended in cases of elevated liver enzymes, and treatment should be interrupted if liver transaminases rise to more than 5 times the upper limit of normal (ULN) or if total bilirubin increases to more than 3 times the ULN. [3]

Variations Between Brands and Indications

While the recommended dosing for ruxolitinib brands may seem similar, there can be variations between brands and indications. It is essential for healthcare professionals to carefully evaluate the specific patient population and indication when selecting a ruxolitinib brand.

Sources:
[1] Jakafi (ruxolitinib) Prescribing Information. (2022). Gilead Sciences, Inc.
[2] Inrebic (ruxolitinib) Prescribing Information. (2020). Incyte Corporation.
[3] Jakafi (ruxolitinib) Prescribing Information. (2022). Gilead Sciences, Inc.

Please note that this is not a comprehensive list of all recommended dosing strategies for ruxolitinib brands, and healthcare professionals should always consult the most recent prescribing information and clinical guidelines for specific patient management.